April 16, 2019
Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)
Media
April 15, 2019
Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 American Association of Clinical Endocrinologists (AACE) Annual
April 12, 2019
Vicore Pharma’s Annual Report 2018 published
April 11, 2019
Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.
April 10, 2019
ACTIVE REMODELING OF CERAMENT® INTO HUMAN BONE CONFIRMED IN UK STUDY
April 10, 2019
Additional patent protection for melflufen granted in the US until 2033
April 10, 2019
Nordic Nanovector: Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin® in DLBCL
April 09, 2019
Targovax ASA: Annual Report 2018
April 03, 2019
Results From Combination of APR-246 with Immuno-Oncology Agents Presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta
April 02, 2019
MIPS continues to be confident about its leading technology